bio superior

Our mission is to revolutionize pulmonary care and save lives by curing lung disease.

BioSuperior Technology, Inc. is a preclinical stage biotherapeutics company developing effective treatment for serious lung illness.

U.S. Market Size

BioSuperior is working to revolutionize the treatment of lung disease.



200,000
people develop ARDS[1] and ALI[2] annually*

80,000
people will die of these illnesses

$30 billion
cost of care per year

50%
of premature babies
born < 29 weeks gestation die due to BPD[3]

[1]ALI = Acute Lung Injury
[2]ARDS = Acute Respiratory Distress Syndrome
[3]BPD = Bronchopulmonary Dysplasia

*Increased significantly since the pandemic

Size of market and cost of care is increasing due to COVID and climate change.

BioSuperior's Innovation

Two platform technologies that deliver potent therapeutics specifically to the deep lung for the treatment of previously untreatable respiratory disease.

#1 BioSurf

Bioengineered lung surfactant for delivery of treatments that combat inflammation, infection, fibrosis, and cancer.

#2 Alveogene

Delivery of protein biologics by gene therapy.



BioSuperior Technology addresses unmet medical needs with two unique drug platforms. BioSURF and Alveogene revolutionize care – shifting the course of action from management, to cure, and repair.

BioSuperior Team

Each member of our team has deep and complementary skills in the chemistry and biology of respiratory medicine and product development.

RUSS LEHRMAN
PhD in Medicinal Chemistry

LUCIA MOKRES
DVM, Doctor of Veterinary Medicine

HONG ZHAO
MS in Chemistry

EHUD GOLDIN
PhD in Biochemistry

$1.5B
Revenue of Products in Market

100+
Years of Experience

17
Number of Patents

Deep experience in pharmaceutical R&D

- Early drug discovery
- Preclinical studies
- Clinical development

Leading academic and clinical researchers are BioSuperior advisors.

Funders, Partners & Milestones

We have secured prestigious partnerships and $500,000+ in funding, including grants from March of Dimes and the National Science Foundation.

Columbia University
Cincinnati Childrens' Hospital
March of Dimes
National Jewish Health
National Science Foundation
Stanford University

Timeline for Lung Surfactant & Gene Therapy

"We are shifting the course of action from management, to cure, and repair."



We are raising additional funds to continue product development and conduct clinical trials for BioSURF and Alveogene.

BioSuperior © 2022 bio-superior.com